Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbiotic-Lung-20: PF-08634404 with combination anticancer agents in advanced NSCLC
jRCT2031250706Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of PF-08634404 and sigvotatug vedotin in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Dose limiting toxicity (DLT) - Phase 1 and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
PF-08634404sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250706.